Comparing palliative surgery with maintenance chemotherapy for metastatic stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two approaches for people with stomach cancer that has spread: having surgery to remove the cancer after a course of 'translational therapy' (a treatment to shrink the tumor), or continuing with standard maintenance chemotherapy. The goal is to see which approach helps people live longer and feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach cancer (a type called adenocarcinoma) that has spread to other parts of the body (metastatic).
- You are generally able to take care of yourself and are up and about more than half of your waking hours (a score of 0 or 1 on a standard scale).
- Your major organs (like blood, liver, and kidneys) are working well enough, based on blood tests.
- You have not had any other cancer in the past 5 years, and you do not have a weakened immune system.
- You are willing to use birth control during the study if needed, and you have not taken part in other clinical trials recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if surgery to remove the stomach and some tumors, after a few months of chemo, helps people whose stomach cancer has spread to only a few nearby spots (like the lining of the belly, liver, or lymph nodes) live longer compared to chemo alone.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This trial is for people with advanced stomach cancer that has shrunk after initial chemotherapy or targeted therapy. It compares whether adding surgery to continued medical treatment is better than staying on medical treatment alone, with the goal of improving outcomes.
This trial compares having surgery to remove stomach cancer versus not having surgery in patients whose cancer in the abdominal lining responded well to initial treatment. The goal is to see which approach helps patients live longer and feel better.
This trial tests whether giving a combination of chemotherapy and an immunotherapy drug before surgery helps shrink stomach cancer tumors and improve outcomes. The treatment is given in the neoadjuvant (before surgery) setting for stomach cancer that is locally advanced but not spread.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
Hear when a new Metastatic Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.